Early Detection and Personalized Treatment of Breast Cancer, Using Comparative Genomics

Tabach Yuval, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research

Prof. Levy-Lahad Ephrat – Director of the Medical Genetics Institute at Shaare Zedek Hospital, Jerusalem


  • Breast cancer is the most common cancer among women.
  • In >70% of cases with suspected hereditary, no mutations could be found in the known susceptibility genes (BRCA1, BRCA2, PALB2, etc.).
  • Establishing a comprehensive panel that identifies the driver of mutations in patients is of particular importance for personalized risk assessment, prevention and treatment of breast cancer.

Our innovation

Using cutting-edge comparative genomics, data integration and machine learning, we developed a comprehensive gene panel that can identify an increased risk of breast cancer and offer personalized treatment options based on PARP inhibitors.  

We aim to develop a platform for predicting the risk for hereditary breast cancer in significantly more patients and offer personalized drug treatment based on the identified mutations.

Application for use:

a. For Breast Cancer patients:

  • Identify the causative mutations Breast cancer patient
  • Optimize and guide treatments

b. for Woman at risk:

  • Risk predictor
  • Optimized treatments  (PARPi)

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: